Antibody-mediated inhibition of FXIIa blocks downstream bradykinin generation

  • J Allergy Clin Immunol. 2018 Oct;142(4):1355-1358. doi: 10.1016/j.jaci.2018.06.014.
Helen Cao  1 ,  Mark Biondo  1 ,  Hadi Lioe  1 ,  Samantha Busfield  1 ,  Veronika Rayzman  1 ,  Bernhard Nieswandt  2 ,  Konrad Bork  3 ,  Leonard C Harrison  4 ,  Priscilla Auyeung  4 ,  Henriette Farkas  5 ,  Dorottya Csuka  5 ,  Matthias Pelzing  1 ,  Steve Dower  1 ,  Michael J Wilson  1 ,  Andrew Nash  1 ,  Marc W Nolte  6 ,  Con Panousis  7
Affiliations
  • 1. CSL Limited, BIO21 Institute, Parkville, Victoria, Australia.
  • 2. Department of Experimental Biomedicine, University Hospital Würzburg and Rudolf Virchow Center for Experimental Biomedicine, University of Würzburg, Würzburg, Germany.
  • 3. Department of Dermatology, Johannes Gutenberg University, Mainz, Germany.
  • 4. Walter and Eliza Hall Institute for Medical Research, Parkville, Victoria, Australia; Department of Medical Biology, University of Melbourne, Parkville, Victoria, Australia.
  • 5. Hungarian Angioedema Center, 3rd Department of Internal Medicine, Semmelweis University, Budapest, Hungary.
  • 6. CSL Behring GmbH Emil-Von-Behring-Straße 76, Marburg, Germany.
  • 7. CSL Limited, BIO21 Institute, Parkville, Victoria, Australia. Electronic address: [email protected].
PMID: 29936101 DOI: 10.1016/j.jaci.2018.06.014
Products